good news, page-24

I supose it depends on your prediction of the potential for decline in fonda sales either through new entrants with arixta generic, or a new product entry. Given the track record of Arixta since the GSK launch I feel positive that we will still be receiving at least some income for the product in another ten years. A tighter market with heavy discounting will discourage further entrants, and if it doesn't, it means the margins are prety atractive which is good news either way.